Abstract
A novel nucleoside analog BMS-181165 with potent activity against varicella-zoster virus was tested for efficacy in a simian varicella virus infection in African green monkeys. BMS-181165 was effective in preventing the development of a rash, decreasing the development of viremia and preventing death in infected monkeys when administered orally at 4, 16 or 64 mg/kg/day. The compound is well orally absorbed in monkeys, between 44 to 50% oral bioavailability, and may prove of value in therapy of varicella-zoster infections in humans.
MeSH terms
-
Administration, Oral
-
Animals
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / blood
-
Antiviral Agents / pharmacokinetics*
-
Biological Availability
-
Chlorocebus aethiops
-
Disease Models, Animal
-
Herpesviridae Infections / complications
-
Herpesviridae Infections / prevention & control*
-
Herpesvirus 1, Cercopithecine*
-
Treatment Outcome
-
Uridine / administration & dosage
-
Uridine / analogs & derivatives*
-
Uridine / blood
-
Uridine / pharmacokinetics
-
Viremia / prevention & control
Substances
-
Antiviral Agents
-
BMS 181165
-
Uridine